rapacuronium (Raplon)

01/01/1999 - "However, the decreased clearance of rapacuronium and its potent metabolite in renal failure suggests that repeated dosing of rapacuronium may lead to prolonged effects in patients with renal failure."
01/01/2002 - "At least in part because of its active metabolite, rapacuronium is highly cumulative in renal failure. "
12/01/2001 - "Rapacuronium undergoes hepatic metabolism: no prolongation of effect has been reported after a single bolus or a short infusion in patients with hepatic or renal failure. "
12/01/2000 - "Persistence of ORG9488 in patients with renal failure might prolong recovery after rapacuronium if target twitch depression is not maintained or with administration of rapacuronium for more than 30 min."
12/01/2000 - "Rapacuronium's plasma clearance and infusion requirement were decreased by renal failure. "

11/01/1999 - "No decrease in plasma clearance of rapacuronium was observed in patients with cirrhosis."
12/01/2000 - "Cirrhosis did not alter the pharmacokinetics of rapacuronium. "
11/01/1999 - "The neuromuscular blocking effect of a single bolus dose of rapacuronium in patients with cirrhosis is not different from that of patients with normal hepatic function. "
11/01/1999 - "Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis."
12/01/2000 - "Recent trials indicate that rapacuronium's pharmacokinetic characteristics are influenced by both renal failure and cirrhosis but the time course of a single bolus dose of 1.5 mg/kg is affected minimally. "

07/01/2002 - "Pulmonary function tests in the present study showed that rapacuronium consistently causes severe bronchoconstriction, confirming clinical case reports of bronchospasm. "
12/01/2005 - "Rapacuronium, a nondepolarizing muscle relaxant, was withdrawn from clinical use because of its association with fatal bronchospasm. "
04/01/2003 - "Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. "
07/01/2002 - "The administration of rapacuronium increases the risk of severe bronchospasm. "
06/01/2002 - "Another possible mechanism for bronchospasm after rapacuronium."

04/01/2000 - "Five adverse experiences were related to rapacuronium administration: Bronchospasm (two instances), tachycardia (one instance), and increased salivation (two instances). "
01/01/2001 - "The main adverse effects of rapacuronium are bronchospasm, hypotension and tachycardia. "
01/01/2001 - "The main drawbacks of rapacuronium are the occurrence of dose-related pulmonary side-effects (increased airway pressure and/or overt bronchospasm) and hypotension and tachycardia. "
01/01/2001 - "The most prominent adverse effects of rapacuronium (tachycardia, hypotension and bronchospasm) are dose-related, and in particular pulmonary adverse effects are observed more frequently under conditions of a rapid-sequence induction in adults. "
12/01/1999 - "Maternal side effects included more tachycardia and skin erythema with rapacuronium; no maternal mortality or morbidity, including bronchospasm, occurred in either group. "

08/01/1999 - "Rapacuronium administration can produce hypotension via mechanisms that do not seem to be related to histamine release. "
01/01/2001 - "The main adverse effects of rapacuronium are bronchospasm, hypotension and tachycardia. "
01/01/2001 - "The main drawbacks of rapacuronium are the occurrence of dose-related pulmonary side-effects (increased airway pressure and/or overt bronchospasm) and hypotension and tachycardia. "
01/01/2001 - "The most prominent adverse effects of rapacuronium (tachycardia, hypotension and bronchospasm) are dose-related, and in particular pulmonary adverse effects are observed more frequently under conditions of a rapid-sequence induction in adults. "